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Abstract
Free fatty acids released from human adipose tissue contain a limited amount of non-esterified poly-cis-unsaturated
fatty acids. In cases of elevated plasma free fatty acids, this condition ultimately leads to a shift from unsaturated to
saturated fatty-acyl chains in membrane phospholipids. Because this shift promotes the physical attractive van
der Waals interactions between phospholipid acyl chains, it increases stiffness of both erythrocyte and
endothelial membranes, which causes a reduction in both insulin-independent and insulin-dependent Class 1
glucose transporters, a reduction in cell membrane functionality, and a decreased microcirculatory blood flow
which results in tissue hypoxia. Against the background of these processes, we review recently published
experimental phospholipid data obtained from Drosophila melanogaster and from human erythrocytes of
controls and patients with type 2 diabetes, with and without retinopathy, along the way free fatty acids
interfere with eye and kidney function in patients with type 2 diabetes and give rise to endoplasmic reticulum
stress, reduced insulin sensitivity, and ischemia.
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Background
To understand, in more detail, the basic concepts of type
2 diabetes pathophysiological mechanisms, we summarize:
the structure of biological membranes, the importance of
membrane flexibility, the effect of increased plasma free
fatty acids (FFAs) on membrane flexibility, the relationship
between increased FFAs and both the development of type
2 diabetes and microvascular complications. In conclu-
sion, we suggest that a long period of increased FFAs must
be avoided to prevent or postpone diabetes-related micro-
vascular complications.
Biological membranes
Compartmentalization, a cell-like structure that separates
the cytoplasm of a cell from the surroundings, is one of
the six basic properties shared by all living cells [1]. After
4 billion years of evolution, these cell-like structures of
the earliest protocells evolved to ‘modern’ cells enclosed
by membranes consisting of phospholipids, the major
constituents of the biological membranes of which the
glycerol-based phospholipids are the major class of
naturally occurring phospholipids. In most cases, glycero-
phospholipids have a saturated fatty acid at position 1 and
an unsaturated fatty acid at position 2 of the glycerol [2].
Saturated fatty acids possess essentially linear alkyl chains
with no double bonds. Conversely, double bonds in unsat-
urated fatty acids are nearly in the cis configuration, which
produces a bend in the fatty-acid chain. Molecules like
palmitoleic acid (C16:1) and oleic acid (C18:1) are bent at
the cis double bond, and the two chain parts form an
angle of 133° [3–6]. This bend has important conse-
quences for the structure and functionality of biological
membranes. Saturated fatty acid chains can pack closely
together, whereas unsaturated fatty acids prevent such
close packing and produce flexible, fluid aggregates. The
two fatty acid chains of a phospholipid molecule (the
hydrocarbon chain region) yield a roughly cylindrical
shape. The hydrocarbon chain region is characterized by
an area (A), that is the surface of the cross-section of the
cylindrical part. Note that unsaturation compared to sat-
uration results in a larger cross-section value for A [7, 8].
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Replacement of saturated acyl chains into mono- or
poly-cis-unsaturated acyl chains of a model phospholipid
membrane increases the area (A) by approximately 15 %,
which involves an increase in the interchain distance of
the fatty acyl chains. Because the attractive van der
Waals forces diminish as 1/r6, the increase in the inter-
chain distance decreases these physical attractive inter-
molecular forces between the fatty acyl chains leading to
an increased membrane flexibility and a decreased mem-
brane rigidity [9, 10]. The unsaturation index (UI) is a
useful parameter for describing the flexibility of a bio-
logical membrane and is calculated by multiplying the
mean number of cis double bonds per fatty-acid residue
by 100 [11]. Arachidonic acid and docosahexaenoic acid
are key fatty acids; a minimal increase in the percentage
of arachidonic acid in phospholipids tails improves
membrane flexibility due to its four double bonds. A
similar effect is seen for docosahexaenoic acid with its
six unsaturated bonds. In other words, an increase in
saturated fatty acids of membrane phospholipids results
in a decrease of membrane flexibility, and is marked by
a reduction of UI.
It is noteworthy that the reversibility of this process
depends on the physical background of the Lennard-
Jones potential, a mathematically straight forward model
that describes the interaction between a pair of neutral
atoms or molecules. Importantly, calculations using a
statistical thermodynamic methodology and Langevin
dynamics indicated that the results of these computer
simulations are in qualitative agreement with the results
of experimental studies [12, 13].
The importance of membrane flexibility
There are at least two senses why membrane flexibility
is important. First, it affects the insertion of glucose
transporters (GLUTs) into cell membranes. GLUT1 is
a monomeric protein with 12 transmembrane helical
segments [14]. During the insertion machinery, the
transporter protein traverses the plasma membrane 12
times in a zigzag fashion, before initiating the folding
necessary to form the three-dimensional structure.
One molecule GLUT1 with a mean cross-section area
of about 1100 Ǻ2 covers an area of about 17 molecules
of a phosphatidylcholine bilayer with saturated fatty
acyl chains [15], which requires a high membrane
flexibility for pore formation. GLUT4 is inserted into
the membrane of intracellular vesicles which demands
flexibility of the vesicular membrane. The GLUT4
containing vesicles take part in a fusion process with
the cell membrane. In the final stage of this process,
fusion proteins induce bending of the plasma mem-
brane bilayer and drive fusion pore formation, which
proceeds more smoothly at an increased flexibility of
both membranes [16, 17]. Thus, reduced membrane
flexibility causes a reduction in all Class 1 glucose
transporters which, in turn, reduces the glucose flux,
and increases the plasma glucose concentration. Thus,
high membrane flexibility represents a key determinant in
glucose transport due to its influence on all Class 1
GLUT proteins.
Second, membrane stiffness induces tissue hypoxia.
The erythrocyte membrane is compositionally very simi-
lar to the vascular endothelium [18]. In support of this,
the UI of red cell membrane phospholipids reported for
healthy controls was 155.4 [19], while the reported UI
for cultured endothelial cells from human umbilical cord
veins was 148.2 ± 6.3 [20]. Therefore, it is likely that if
the erythrocyte membrane is selectively affected in type
2 diabetes, the endothelium could also be affected
with the expected consequences of vascular disfunc-
tion [21, 22]. In capillaries in which the size of red
blood cells is of the same order of magnitude as the
lumen (about 8 μm) flexibility is an important deter-
minant of blood flow. Increased stiffness of both mem-
branes may decrease the microcirculatory blood flow. This
reduction of the microcirculatory blood flow causes re-
duced oxygen uptake in tissues and thus hypoxia [23, 24].
Eukaryotic cells use oxygen as the final electron acceptor of
the oxidative phosphorylation step, to drive ATP synthesis.
And that means decreases in O2 may be an important
player in the impaired ATP production of (skeletal muscle)
mitochondria in type 2 diabetes [25–28]. In more general
terms, a reduction in membrane flexibility affects the
continuous flux of ATP production (i.e., energy) re-
quired for a proper functioning of all living cells. For
the reader’s mind-set, a single cell consumes around 10
million molecules of ATP every second, giving a total
turnover of ATP of around 80 kg per day [1].
Increase of free fatty acids affects membrane flexibility
Type 2 diabetes and its prediabetic phase, gestational
diabetes mellitus, and obesity are characterized by in-
creased plasma FFAs [29–35]. As discussed in the afore-
mentioned paragraph, the cause of this phenomenon is a
reduction of GLUTs which reduces the ATP production
via the coupled metabolic reaction chain comprising gly-
colysis, tricarboxylic acid cycle, and oxidative phosphoryl-
ation. This alarming situation demands for an increase in
ATP via ß-oxidation of circulating FFAs and stimulates so
adipose-tissue lipolysis. We propose the latter is the classic
trigger for the onset of type 2 diabetes and its vascular
lesions. It is currently widely believed that the release of
fatty acids in humans is proportional to the fatty-acid con-
tent in adipose tissue [35]. The released FFA-pool from
human white cells had approximately 110- and 9-fold
decreased percentages of docosahexaenoic acid (C22:6)
and arachidonic acid (C20:4), respectively, compared with
the human serum pool (Table 1). We calculated the UIs of
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released FFAs from human white fat cells [36] and serum
FFAs in healthy controls [37] and, as was to be expected,
the former was substantially lower (85.5 and 191.9,
respectively; Δ = 55.4 %) (Table 1). Thus, an increased
release of FFAs from adipose tissue into the circulation
elevates the plasma concentration of saturated fatty acids.
So, a shift is forced from unsaturated to saturated fatty-
acyl chains in phospholipids of both the erythrocyte mem-
brane and the vascular endothelium [10]. Summarized, we
have now a conceptual argument that increased FFAs
cause a reduction in membrane flexibility which, in turn,
affects oxygen transport and, thus, a continuous flux of
ATP production (i.e., energy) necessary for a proper func-
tioning of living cells. A number of papers have reported
examples of reduced membrane flexibility; a review by
Cho et al. indicated that patients with type 2 diabetes
exhibited reduced erythrocyte deformability compared to
healthy controls [38].
This concept is in accordance with the calculated UIs
based on the data coming from a study on erythrocyte
Table 1 Unsaturation index of non-esterified fatty acids released from human white fat cells, and human serum lipids of
healthy subjects
Fatty acids Released from white fatt cellsa Serum lipidsb
















C18:2 n-6 15.74 31.49 27.47 54.94
C20:2 n-9 0.02 0.03
C20:2 n-6 0.23 0.46
C18:3 n-3 0.73 2.20 2.48 7.44
C18:3 n-6 0.05 0.15
C20:3 n-6 0.21 0.64
C20:3 n-3 0.03 0.08
C20:4 n-6 0.51 2.04 4.48 17.92
C20:4 n-3 0.04 0.14
C22:4 n-6 0.08 0.33
C20:5 n-3 0.09 0.45 1.56 7.80
C22:5 n-6 0.01 0.04
C22:5 n-3 0.09 0.45
C22:6 n-3 0.12 0.70 13.36 80.16
Total 100.00 100.00
UI 85.53 191.86
For conversion to mol%, athe data listed by Raclot et al. [36] were multiplied by: (MWFFA)
-1 · 103 · 0. 272, and bthose by Wang et al. [37] by 0. 142. The unsaturation
index was calculated as the mean number of cis double bonds per fatty-acid residue multiplied by 100. SFA saturated fatty acid, MUFA monounsaturated fatty acid,
MW, molecular weight
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phospholipid and poly-cis-unsaturated fatty-acid (PUFA)
composition in diabetic retinopathy [39]. Categorizing
fatty acids in saturated fatty acids, mono-unsaturated
fatty acids, and PUFAs, the phospholipid fatty-acid
groups’ data from controls and patients with type 2
diabetes without and with retinopathy revealed a sub-
stantial time-dependent shift from unsaturation into
saturation (Table 2). Accordingly, the calculated UI was
substantially lower in individuals with type 2 diabetes
without retinopathy than in healthy controls (134.3 and
155.4, respectively; Δ = 13.5 %), and the calculated mean
UI for subjects with type 2 diabetes with mild, moderate,
and severe diabetic retinopathy was substantially lower
than in individuals with type 2 diabetes without diabetic
retinopathy (123.4 and 134.3, respectively; Δ = 8.1 %)
[19, 39]. The observed declining trend of UIs underlines
the hypothesis that the onset of type 2 diabetes is
characterized by a substantial increase of plasma satu-
rated fatty acids which includes a decrease in UI and a
concomitant decrease in membrane flexibility. The data
are also in agreement with the notion that, after frank
type 2 diabetes, an ongoing decrease of UI effectuates
the development of vascular and neurological lesions,
due to an ongoing decrease of membrane flexibility and
functionality. It is interesting to note that (1) individuals
with an impaired glucose tolerance test have a signifi-
cantly increased FFA concentration compared to healthy
controls [40], (2) the increase in FFAs is augmented after
the onset of type 2 diabetes [40], and (3) patients with
type 2 diabetes exhibited significantly reduced erythro-
cyte flexibility compared to healthy controls [41]. Thus,
an increase in FFAs causes an increase in plasma satu-
rated fatty acids which, in turn, creates an shift from
unsaturation into saturation of biological membranes
which affects their flexibility and functionality.
This concept is inherent in all biological membranes.
In this context, I would like to recall a recent report
from the Academy of Medical Royal Colleges [42], which
quite rightly states that complications of type 2 diabetes
are common and affect all systems: diabetic retinopathy,
nephropathy, neuropathy, microvascular complications,
ulcers and sexual dysfunction.
A recent study demonstrated that Drosophila melanoga-
ster’s phototransduction (the response to light) depends
on the degree of saturation of its phospholipid membrane
[43]. The proportion of polyunsaturated phospholipids in
flies reared on a yeast diet, lacking PUFAs, was signifi-
cantly reduced, but was rescued by adding a single type of
PUFA (α-linolenic [18:3] or linoleic acid [18:2]) to the diet.
Photoreceptors from yeast-reared flies showed a substan-
tial increase in latency and time to peak light response
compared to control flies. This phenomenon disappeared
by adding either α-linolenic (C18:3) or linoleic acid
(C18:2) to the diet. The authors underlined the reverse
relationship between the mean number of cis double
bonds per fatty-acid residue of a biological membrane and
its stiffness [44, 45]. Another recent study [46] showed
that deficiency of PUFAs strongly affected the synaptic
transmission in the visual system of Drosophila melanoga-
ster fly’s, which defects were rescued by diets containing
ω-3 or ω-6 PUFAs alone or in combination. In contrast to
Nyengaard et al., we propose that the capillary closure,
observed by proliferative retinopathy in retinas from rats,
results from membrane stiffness and hypoxia [24]. Data of
these studies need to be carefully examined as the animal
model results do not compulsorily translate into human
medicine. However, mammalian retinal ganglion cells
phototransduction cascades show similarity with fly visual
transduction. It is noteworthy that the Drosophila melano-
gaster subgroup diverged from the cluster of the three
major groups in the melanogaster group during the Late
to Middle Eocene (35–45 million years ago) [47].
Increased saturated fatty acids and development of type
2 diabetes
In a previous paper [10], we explained the consequence of
increased fatty-acid exposure in relation to the risk of pro-
gression to type 2 diabetes (Fig. 1). Shortly, we hypothesized
that the involved genes cause an elevation of plasma FFAs
which leads to an increase in plasma saturated FFAs and,
consequently, to a decrease in membrane phospholipid UI,
as seen in erythrocytes. The result is an increase in mem-
brane stiffness and a partial loss off all GLUTs. The conse-
quence of this reasoning is a decrease in both glucose
effectiveness and insulin sensitivity as seen in individuals
with type 2 diabetes compared to healthy controls (Table 3).
This hypothesis had to be demonstrated [48–51]. This
process causes an increase in plasma glucose and insulin
concentrations until ß-cell failure occurs and the condition
of glucose tolerance gives way to frank type 2 diabetes.
The fundamental coincidence between the experimental
Drosophila melanogaster data [43, 46] and the UI data
from subjects with type 2 diabetes with and without
retinopathy [19, 39] support our working hypothesis
that saturated FFAs influence membrane flexibility and,
consequently, membrane functionality.
Table 2 Erythrocyte fatty acid composition of controls,
individuals with type 2 diabetes without diabetic retinopathy,









SFAs (%) 41.83 43.99 46.61
MUFAs (%) 18.85 21.68 21.26
PUFAs (%) 37.97 31.92 29.47
SFA saturated fatty acid, MUFA monounsaturated fatty acid, PUFA
poly-cis-unsaturated fatty acid
aOriginal data listed by Koehrer et al. [39]
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Additionally, we discussed [52] the consequences of
Liposin II infusions, as reported by Shuman’s group [53].
We calculated the UIs of Liposin II and serum FFAs in
healthy controls and the former was substantially lower
(162 and 191.9, respectively; Δ = 15.2 %), which is the
principal cause of the decrease in all functional Class I
glucose transporters. In other words, this decrease in
glucose transporters became visible as the transmem-
brane “inhibition of glucose transport” [53].
We already mentioned the very similar composition of
the vascular endothelium and the erythrocyte mem-
brane. Consistent with this concept is the observation
that an elevation of the circulating FFA concentration in
lean healthy humans causes endothelial dysfunction,
which is similar to that observed in obese individuals
with reduced insulin sensitivity, and with or without type
2 diabetes [54]. Also, the authors suggested that it is this
dysfunction, which over time is likely to increase greatly
the risk of macrovascular disease. We can scarcely avoid
the inference that a decrease in membrane flexibility, due
to an increase in FFAs, is the underlying cause of the well-
known relationship between endothelium dysfunction and
type 2 diabetes [55].
Microvascular complications
In the section ‘The importance of membrane flexibility’,
we discussed an increase in plasma unsaturated fatty acids
and its implications for diabetic retinopathy; however,
increased plasma FFAs also play a crucial role in the
relentless progress of diabetic kidney disease and affect
function and survival of podocytes [56]. Previous studies
of podocyte function showed results, which are in support
of the working hypothesis; for example, derangements of
the architecture of podocytes and glomerular endothelial
Fig. 1 Proposed steps in the development of type 2 diabetes model. Although the results of genome-wide screen for type 2 diabetes susceptibility
genes is still being debated, we hypothesize that the involved genes of the disease lead to an increase in plasma free fatty acids; FFA: free fatty acid;
GLUT: glucose transporter
Table 3 Values of glucose effectiveness (SG) and insulin sensitivity (SI) for minimal model
Units SG Control subjects Type 2 diabetes P Compart-ment Tracher Ref.
min-1 0.016 ± 0.001 0.010 ± 0.001 <0.01 one no 48
0.023 ± 0.012 0.013 ± 0.001 <0.05 one no 49
0.023 ± 0.012 0.016 ± 0.009 <0.001 one no 50a
h-1 1.2 ± 0.16 0.81 ± 0.11 <0.001 one no 51
0.41 ± 0.04 0.33 ± 0.02 <0.001 two 13C 51
0.52 ± 0.05 0.37 ± 0.02 <0.001 two 2H 51
Units SI
10-4 min-1 (mU/L)-1 11.8 ± 2.6 6.7 ± 0.8 <0.01 one no 49
13.45 ± 11.12 5.31 ± 3.98 <0.01 one no 50 a
pmol L-1 h-1 0.0062 ± 0.0006 0.0019 ± 0.0006 <0.01 one no 51
0.0082 ± 0.0012 0.0036 ± 0.0006 <0.001 two 13C 51
0.0098 ± 0.0013 0.0042 ± 0.0008 <0.001 two 2H 51
aMore than 10 years before the development of type 2 diabetes
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cells have significant effects on kidney function in patients
with type 2 diabetes [57]. We suggest that an increased
stiffness of both podocyte cell membrane and glomerular
endothelium the driving force is behind podocyte detach-
ment and reduced endothelial cell fenestration in patients
with type 2 diabetes.
Reperfusion of ischemic tissues is often associated with
microvascular injury. These “activated” endothelial cells
produce more reactive oxygen species. In 2009, a study
examined the role of a large number of recently iden-
tified factors that contribute to podocytopathies in dia-
betic kidney disease and found a number are reactive
oxygen species [58].
Decreased microcirculatory flow causes reduced oxygen
uptake and endoplasmic reticulum failure as seen in sub-
jects with newly-detected type 2 diabetes and subjects
with impaired glucose tolerance [59]. The generation of
insufficient oxidative potential for the formation of disul-
phide bonds may result in an accumulation of unfolded or
misfolded proteins in the lumen of the endoplasmic
reticulum, which is referred to as endoplasmic reticulum
stress. Endoplasmic reticulum stress has also been
found in the tubulointerstitial and glomerular compa-
rtments of renal biopsies obtained from patients with
diabetic nephropathy [60, 61].
In the kidney, glomerular podocytes are insulin-sensitive
cells. Lennon et al. demonstrated that human po-
docytes cultured in vitro with palmitate lost their
insulin-stimulated glucose uptake [62]. The authors
suggest that insulin-sensitizing agents such as PPARγ
agonists may have direct beneficial effects on podo-
cytes of individuals with type 2 diabetes. Currently, we
understand that the ultimate effect of insulin on the
transmembrane glucose transport depends on both its
plasma concentration and the plasma FFA concentration
that determines the degree of membrane flexibility
[16, 63–66]. That said, to give more concrete content
to the wide-ranging discussion on the type 2 diabetes
pathophysiology, we propose to replace the word-
combination ‘insulin resistance’ by ‘reduced mem-
brane flexibility’. Finally, in patients with impaired
glucose tolerance, the ability of the liver to extract
FFA from the circulation is impaired [67]. In this
regard, it is of interest that studies have also identified
increases in intramyocellular lipid in individuals with
an increased relative risk of type 2 diabetes [68].
According to the working hypothesis, tissue hypoxia
disturbs mitochondrial β-oxidation of intramyocellular
and intrahepatic FFAs.
Summary
Glycerophospholipids, the major class of naturally occur-
ring membrane phospholipids, have a saturated fatty acid
at position 1 and an unsaturated fatty acid at position 2 of
the glycerol. In contrast to saturated fatty acids, unsatur-
ated fatty acids have, due to the presence of one or more
carbon-carbon double bonds, a non-linear chain. As a
result, saturated fatty acids can self-assemble closely
together, whereas unsaturated fatty acids prevent such
close packing and produce more flexible aggregates. This
phenomenon has a great impact on the flexibility of
phospholipid membranes. The unsaturation index (UI) is
a useful parameter for describing the flexibility of a
biological membrane and is calculated by multiplying the
mean number of cis double bonds per fatty-acid residue
by 100. An increased UI implies more membrane flexibil-
ity, and a decreased UI implies more membrane stiffness.
The released non-esterified fatty-acid pool from human
white cells had approximately 110- and 9-fold decreased
percentages of docosahexaenoic acid (C22:6) and arachi-
donic acid (C20:4), respectively, compared to the human
serum FFA pool. Thus, an increased release of FFAs from
adipose tissue into the circulation, a characteristic of both
the prediabetic and the diabetic phase, elevates the plasma
concentration of saturated fatty acids which results in a
shift from unsaturated to saturated fatty-acyl chains in
phospholipids of both the erythrocyte membrane and the
vascular endothelium. This will cause an increase of
diabetes-specific microvascular complications as demon-
strated by two recent publications on Drosophila melano-
gaster’s phototransduction, and the synaptic transmission
in the visual system of Drosophila melanogaster fly’s, and
a study on human erythrocyte phospholipid and PUFA
composition in diabetic retinopathy. These studies provide
new insight about the relationship between impaired
membrane flexibility and vascular complications of type
2 diabetes.
Conclusions
Building on the presented evidence, we suggest that
chronically elevated plasma FFAs must be avoided to
prevent or postpone reduction of membrane flexibility,
which may be the major cause of diabetes-specific
complications. We are not concerned with the details of
our hypothesis, but we hope that the bigger picture is
correct. More research is necessary to better understand
the idea of early systemic cell membrane dysfunction.
Abbreviations
FFA: free fatty acid; PUFA: poly-cis-unsaturated fatty acid;
UI: unsaturation index.
Competing interests
The author declares that he has no competing interests.
Disclosure of grants
No funding support was received from a third party for this study.
Received: 11 November 2015 Accepted: 10 April 2016
Weijers Journal of Diabetes & Metabolic Disorders  (2016) 15:13 Page 6 of 8
References
1. Lane N. The vital question: why is live the way it is? London: Profile
Books; 2015.
2. Garrett RH, Grisham CM. Biochemistry. 2nd ed. Fort Worth: Saunders College
Publishing; 1999.
3. Cho SI, Craven BM. Commensurate molecules in isostructural crystals of
cholesteryl cis- and trans-9-hexadecenoate. J Lipid Res. 1987;28:80–6.
4. Abrahamsson S, Ryderstedt-Nahringbauer I. The crystal structure of the
low-melting form of oleic acid. Acta Crys. 1962;15:1261–8.
5. PubChem Compound Database; CID=445638. Available from:
https://pubchem.ncbi.nlm.nih.gov/compound/palmitoleic_acid.
6. PubChem Compound Database; CID=445639. Available from:
https://pubchem.ncbi.nlm.nih.gov/compound/oleic_acid.
7. Kučerka N, Liu Y, Chu N, Petrache HI, Tristram-Nagle S, Nagle JF. Structure of
fully hydrated fluid phase DMPC and DLPC lipid bilayers using X-ray
scattering from oriented multilamellar arrays and from unilamellar vesicles.
Biophys J. 2005;88:2626–37.
8. Nagle JF, Tristram-Nagle S. Structure of lipid bilayers. Biochim Biophys Acta.
2000;1469:159–95.
9. Kučerka N, Heberle FA, Pan J, Katsaras J. Structural significance of lipid
diversity as studied by small angle neutron and X-ray scattering.
Membranes. 2015;5:454–72.
10. Weijers RN. Lipid composition of cell membranes and its relevance in type
2 diabetes mellitus. Curr Diabetes Rev. 2012;8:390–400.
11. Baur LA, O’Conner J, Pan DA, Storlien LH. Relationships between maternal
risk of insulin resistance and the child’s muscle membrane fatty acid
composition. Diabetes. 1999;48:112–6.
12. Israelachvili NJ. The nature of van der Waals forces. Contemp Phys.
1974;15:159–78.
13. Nir S, Andersen M. Van der Waals interactions between cell surfaces.
J Membrane Biol. 1977;31:1–18.
14. Salas-Burgos A, Iserovich P, Zuniga F, Vera JC, Fischbarg J. Predicting the
three-dimensional structure of the human facilitative glucose transporter
Glut1 by a novel evolutionary homology strategy: insights on the molecular
mechanism of substrate migration, and binding sites for glucose and
inhibitory molecules. Biophys J. 2004;87:2990–9.
15. Büldt G, Gally HU, Seelig J. Neutron diffraction studies on
phosphatidylcholine model membranes. J Mol Biol. 1979;134:673–91.
16. Marrink SJ, Mark AL. The mechanism of vesicle fusion as revealed by
molecular dynamics simulation. J Am Chem Soc. 2003;125:11144–5.
17. Ravoo BJ. Membrane fusion of vesicles of oligomerisable lipids. PhD
Thesis, Rijksuniversiteit Groningen,1998. Available from: http://irs.ub.rug.
nl/ppn/291236774.
18. Dougherty RM, Galli G, Ferro-Luzzi A, Iacono JM. Lipid and phospholipid
fatty acid composition of plasma, red blood cells, and platelets and how
they are affected by dietary lipids: a study of normal subjects from Italy,
Finland and the USA. Am J Clin Nutr. 1987;45:443–55.
19. Weijers RNM. Unsaturation index and type 2 diabetes: unknown, unloved.
World J Meta-Anal. 2015;3:89–92.
20. Vossen RCRM, van Dam-Mieras MCE, Lemmens PJMR, Hornstra G, Zwaal RFA.
“Membrane fatty acid composition and endothelial cell functional properties”
in Fatty Acid Modification and Endothelial Cell Reactivity [Thesis], ed. RCRM.
Maastricht, The Netherlands: Vossen Universitaire Pers Maastricht; 1993.
21. Guerci B, Kearney-Schwarz A, Böhme P, Zannad F, Drouin P. Endothelial
dysfunction and type 2 diabetes [review]. Diabet Metab. 2001;27:436–47.
22. Georgescu A. Vascular dysfunction in diabetes: The endothelial progenitor
cells as a new therapeutic strategy. World J Diabetes. 2011;15:92–7.
23. Carvalho C, Santos RX, Cardoso S, Correia SC, Moreira PI. Chronic
hypoxia, type 2 diabetes and Alzheimer’s disease: a dangerous triad. In:
Vordermark D, editor. Hypoxia: causes, types and management.
New York: Nova; 2013. p. 21–34.
24. Neyengaard JR, Ido Y, Kilo C, Williamson JR. Interactions between
hyperglycemia and hypoxia: implications for diabetic retinopathy.
Diabetes. 2004;53:2931–38.
25. Shi X, Burkart A, Nicoloro SM, Czech MP, Straubhaar J, Corvera S. Paradoxial
effect of mitochondrial respiratory chain impairment on insulin signaling
and glucose transport in adipose cells. J Biol Chem. 2008;283:30658–67.
26. Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes.
Science. 2005;307:384–7.
27. Mootha VK, Lindgren CM, Eriksson K-F, Subramanian A, Sihag S, Lehar J, et
al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are
coordinately downregulated in human diabetes. Nat Genet.
2003;34:267–73.
28. Kelly DE, He J, Menshikova EV, Ritov VB. Dysfunction of mitochondria in
human skeletal muscle in type 2 diabetes. Diabetes. 2002;51:2944–50.
29. Reaven GM, Hollenbeck CB, Jeng CY, Wu MS, Chen Y-DI. Measurement of
plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with
NIDDM. Diabetes. 1988;37:1020–4.
30. Gordon ES. Non-esterified fatty acids in blood of obese and lean subjects.
Am J Clin Nutr. 1960;8:740–7.
31. Jensen MD, Haymond MW, Rizza RA, Cryer PE, Miles JM. Influence of
body fat distribution on free fatty acid metabolism in obesity. J Clin
Invest. 1989;83:1168–73.
32. Björntorp P, Bergman H, Varnauskas E. Plasma free fatty acid turnover rate in
obesity. Acta Med Scand. 1969;185:351–6.
33. Charles MA, Eschwege E, Thibult N, Claude JR, Warnet JM, Rosselin GE, et al.
The role of non-esterified fatty acids in the deterioration of glucose
tolerance in Caucasian subjects: results of the Paris Prospective Study.
Diabetologia. 1997;40:1101–6.
34. Paolisso G, Tataranni PA, Foley JE, Bogardus C, Howard BV, Ravussin E.
A high concentration of fasting plasma non-esterified fatty acids is a risk
factor for the development of NIDDM. Diabetologia. 1995;38:1213–7.
35. Hudgins LC, Hirsch J. Changes in abdominal and gluteal adipose-tissue fatty
acid compositions in obese subjects after weight gain and weight loss. Am
J Clin Nutr. 1991;53:1372–7.
36. Raclot T, Langin D, Lafontan M, Groscolas R. Selective release of
human adipocyte fatty acids according to molecular structure.
Biochem J. 1997;324:911–5.
37. Wang S, Ma A, Song S, Quan Q, Zhao X, Zheng X. Fasting serum free fatty
acid composition, waist/hip ratio and insulin activity in essential
hypertensive patients. Hypertens Res. 2008;31:623–32.
38. Gupta AK, Ravussin E, Johannsen DL, Stull AJ, Cefalu WT, Johnson WD.
Endothelial dysfunction: an early cardiovascular risk marker in asymptomatic
individuals with prediabetes. Brit J Med Res. 2012;2:413–23.
39. Koehrer P, Saab S, Berdeaux O, Isaïco R, Grégoire S, Cabaret S, et al.
Erythrocyte phospholipid and polyunsaturated fatty acid composition in
diabetic retinopathy. PLoS One. 2014;9:e106912.
40. Laws A, Hoen HM, Selby JV, Saad MF, Haffner SM, Howard BV. Differences in
insulin suppression of free fatty acid levels by gender and glucose tolerance
status. Relation to plasma triglyceride and apolipoprotein B concentrations.
Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Aterioscler
Thromb Vasc Biol. 1997;17:64–71.
41. Cho YI, Moony MP, Cho DJ. Hemorheological disorders in diabetes mellitus
[review]. J Diabetes Sci Technol. 2008;2:1130–8.
42. Academy of Medical Royal Colleges. Exercise: the miracle cure and the role
of the doctor in promoting it. 2015. Available from: URL: http://www.aomrc.
org.uk/doc_download/9821
43. Randall AS, Liu C-H, Chu B, Zhang Q, Dongre SA, Juusola M, et al. Speed
and sensitivity of phototransduction in Drosophila depend on degree of
saturation of membrane phospholipids. J Neurosci. 2015;35:2731–46.
44. Brenner RR. Effect of unsaturated acids on membrane structure and enzyme
kinetics. Prog Lipid Res. 1984;23:69–96.
45. Rawicz W, Olbrich KC, McIntosh T, Needham D, Evans E. Effect of chain
length and unsaturation on elasticity of lipid bilayers. Biophys J. 2000;79:
328–39.
46. Ziegler AB, Ménagé C, Grégoire S, Garcia T, Ferveur J-F, Bretillon L. Lack of
dietary polyunsaturated fatty acids causes synapse dysfunction in the
drosophila visual system. PLoS One. 2015;10:e0135353.
47. Tamura K, Subramanian S, Kumar S. Temporal patterns of fruit fly
(Drosophila) evolution revealed by mutation clocks. Mol Biol Evol.
2004;21:36–44.
48. Basu A, Caumo A, Bettini F, Gelisio A, Alzaid A, Cobelli C, et al. Impaired
basal glucose effectiveness in NIDDM. Contribution of defects in glucose
disappearance and production, measured using an optimized minimal
model independent protocol. Diabetes. 1997;46:421–32.
49. Nagasaka S, Tokuyama K, Kusaka I, Hayashi H, Rokkaku K, Nakamura T, et al.
Endogenous glucose production and glucose effectiveness in type 2
diabetic subjects derived from stable-labeled minimal model approach.
Diabetes. 1999;48:1054–60.
50. Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn CR.
Role of glucose and insulin resistance in development of type 2 diabetes
mellitus: results of a 25-year follow-up study. Lancet. 1992;340:925–9.
Weijers Journal of Diabetes & Metabolic Disorders  (2016) 15:13 Page 7 of 8
51. Bluck LJ, Clapperton AT, Coward WA. 13C- and 2H labelled glucose
compared for minimal model estimates of glucose metabolism in man.
Clin Sci. 2005;109:513–21.
52. Weijers RNM. Membrane flexibility and cellular energy management in type
2 diabetes, gestational diabetes, and obesity. EMJ Diabet. 2014;2:65–72.
53. Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL, Cline GW, et al.
Mechanism of free fatty acid-induced insulin resistance in humans. J Clin
Invest. 1996;97:2859–65.
54. Steinberg HO, Tarshoby M, Monestel R, Hook G, Cronin J, Johnson A, et al.
Elevated circulating free fatty acid levels impair endothelium-dependent
vasodilation. J Clin Invest. 1997;5:1230–9.
55. Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical
perspective. Endocr Rev. 2001;22:36–52.
56. Sieber J, Jehle AW. Free fatty acids and their metabolism affect function and
survival of podocytes. Front Endocrinol. 2014;5:186.
57. Weil EJ, Lemley KV, Mason CC, Yee B, Jones LI, Blouch K, et al.
Podocyte detachment and reduced glomerular capillary endothelial
fenestration promote kidney disease in type 2 diabetic nephropathy.
Kidney Int. 2012;82:1010–7.
58. Stitt-Cavanagh E, MacLeod L, Kennedy C. The podocyte in diabetic kidney
disease. ScientificWorldJournal. 2009;9:1127–39.
59. Eriksson KF, Lindgärde F. Prevention of type 2 (non-insulin-dependent)
diabetes mellitus by diet and physical exercise. The 6-year Malmö feasibility
study. Diabetologia. 1991;34:891–8.
60. Cunard R, Sharma K. The endoplasmic reticulum stress response and
diabetic kidney disease. Am J Physiol Renal Physiol. 2011;300:F1054–61.
61. Sieber J, Lindenmeyer MT, Kampe K, Campbell KN, Cohen CD, Hopfer H, et
al. Regulation of podocyte survival and endoplasmic reticulum stress by
fatty acids. Am J Physiol Renal Physiol. 2010;299:F821–9.
62. Lennon R, Pons D, Sabin MA, Wei C, Shield JP, Coward RJ, et al. Saturated
fatty acids induce insulin resistance in human podocytes: implications for
diabetic nephropathy. Nephrol Dial Transplant. 2009;24:3288–96.
63. Ohara-Imaizumi M, Nishiwaki C, Nakamichi Y, Kikuta T, Nagai S, Nagamatsu
S. Correlation of syntaxin-1 and SNAP-25 clusters with docking and fusion
of insulin granules analysed by total internal reflexion fluorescence
microscopy. Diabetologia. 2004;47:2200–7.
64. Nagamatsu S, Ohara-Imaizumi M, Nakamichi Y, Kikuta T, Nishiwaki C.
Imaging docking and fusion of insulin granules induced by antidiabetes
agents: sulfonylurea and glinide drugs preferentially mediate the fusion
of newcomer, but not previously docked, insulin granules. Diabetes.
2006;55:2819–25.
65. Guillausseau PJ, Meas T, Virally M, Laloi-Michelin M, Médeau V, Kevorkian JP.
Abnormalities in insulin secretion in type 2 diabetes mellitus. Diabetes
Metab. 2008;34 Suppl 2:S43–48.
66. Ratzmann KP, Schulz B, Heinke P, Michaelis D. Quantitative and qualitative
changes in the early insulin response to glucose in subjects with impaired
carbohydrate tolerance. Diabetes Care. 1981;4:85–91.
67. Iozzo P, Turpeinen AK, Takala T, Oikonen V, Bergman J, Grönroos T, et al.
Defective liver disposal of free fatty acids in patients with impaired glucose
tolerance. J Clin Endocrinol Metab. 2004;89:3496–502.
68. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired
mitochondrial activity in the insulin-resistant offspring of patients with type
2diabetes. N Engl J Med. 2004;350:664–71.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Weijers Journal of Diabetes & Metabolic Disorders  (2016) 15:13 Page 8 of 8
